NeoGenomics (NASDAQ: NEO) reported Q2 EPS of $0.05, $0.01 better than the analyst estimate of $0.04. Revenue for the quarter came in at $67.7 million versus the consensus estimate of $66.18 million.

For earnings history and earnings-related data on NeoGenomics (NEO) click here.